[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367396-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367396-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-novel-3d-high-throughput-phenotypic-drug-screening-pipeline-to-identify-drugs-with-repurposing-potential-for-the-treatment-of-ovarian-cancer","A Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer","","A novel precision approach for ovarian cancer addresses high recurrence and chemotherapy resistance by enabling rapid drug repurposing. Using patient-derived polyclonal spheroids from ascites fluid as a clinically relevant 3D model, a high-throughput screening pipeline evaluates both cytotoxicity and anti-migratory activity across FDA-approved, investigational, and newly approved compounds. Results show limited agreement between conventional 2D efficacy and 3D phenotypes. Rapamycin displayed weak single-agent activity but synergized with cisplatin or paclitaxel, enhancing in vitro killing and reducing tumor burden in vivo, supporting translation into clinical trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-novel-3d-high-throughput-phenotypic-drug-screening-pipeline-to-identify-drugs-with-repurposing-potential-for-the-treatment-of-ovarian-cancer/367396/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-novel-3d-high-throughput-phenotypic-drug-screening-pipeline-to-identify-drugs-with-repurposing-potential-for-the-treatment-of-ovarian-cancer/367396.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is drug repurposing particularly attractive for ovarian cancer treatment?","Question",{"text":63,"@type":64},"Ovarian cancer has limited effective precision medicine options because reliable outcome-predicting biomarkers are scarce. Repurposing leverages existing pharmacological knowledge to rapidly identify new therapies for ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What model is used to better reflect ovarian cancer behavior during drug testing?",{"text":68,"@type":64},"Patient-derived polyclonal spheroids isolated from ascites fluid are used as a 3D model that closely mimics clinical ovarian cancer behavior, improving relevance compared with traditional 2D systems.",{"name":70,"@type":61,"acceptedAnswer":71},"How did rapamycin perform in combination therapy compared with monotherapy?",{"text":72,"@type":64},"Rapamycin showed limited activity as a monotherapy, but it synergized effectively with standard treatments such as cisplatin and paclitaxel in vitro, and in combination with platinum-based therapy it increased cytotoxicity and reduced tumor burden in a syngeneic in vivo model.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367396,1790198838,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","RESEARCH ARTICLE  \n[www.advhealthmat.de](www.advhealthmat.de)  \nA Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer  \nNazanin Karimnia, Amy L. Wilson, Brittany R. Doran, Jennie Do, Amelia Matthews, Gwo Y. Ho, Magdalena Plebanski, Thomas W. Jobling, Andrew N. Stephens, and Maree Bilandzic*  \nOvarian cancer (OC) poses a signiﬁcant clinical challenge due to its high recurrence rates and resistance to standard therapies, particularly in advanced stages where recurrence is common, and treatment is predominantly palliative. Personalized treatments, while eﬀective in other cancers, remain underutilized in OC due to a lack of reliable biomarkers predicting clinical outcomes. Accordingly, precision medicine approaches are limited, with PARP inhibitors showing eﬃcacy only in speciﬁc genetic contexts. Drug repurposing oﬀers a promising, rapidly translatable strategy by leveraging existing pharmacological data to identify new treatments for OC. Patient-derived polyclonal spheroids, isolated from ascites ﬂuid closely mimic the clinical behavior of OC, providing a valuable model for drug testing. Using these spheroids, a high-throughput drug screening pipeline capable of evaluating both cytotoxicity and anti-migratory properties of a diverse drug library, including FDA-approved, investigational, and newly approved compounds is developed. The ﬁndings highlight the importance of 3D culture systems, revealing a poor correlation between drug eﬃcacy in traditional 2D models and more clinically relevant 3D spheroids. This approach has expedited the identiﬁcation of promising candidates, such as rapamycin, which demonstrated limited activity as a monotherapy but synergized eﬀectively with standard treatments like cisplatin and paclitaxel in vitro. In combination with platinum-based therapy, Rapamycin led to signiﬁcant in vitro cytotoxicity and a marked reduction in tumor burden in a syngeneic in vivo model. This proof-of-concept study underscores the potential of drug repurposing to rapidly advance new treatments into clinical trials for OC, oﬀering renewed hope for patients with advanced disease.  \n1. Introduction  \nOver 75% of ovarian cancer (OC) patients are diagnosed with late-stage disease and extensive tumor dissemination throughout the abdominal cavity.[1,2] Standard ﬁrst-line treatment typically includes cytoreductive surgery with combination platinum/taxane chemotherapy.[3–5] Whilst initially eﬀective, recurrence with chemo-resistant disease occurs in ≈85% of patients which is the primary cause of mortality.[6–9] Therapeutic failure marked by recurrence and resistance represents the major roadblock to the effective management of ovarian cancer with over 90% of patients eventually developing resistance to treatment. [1] Although personalized treatments have demonstrated great success in the management of other cancers, only a small subset of ovarian cancer patients beneﬁt from such approaches leaving most with metastatic OC with limited treatment options, often focusing on symptom palliation rather than curative outcomes.  \nOvarian cancer patients can be stratiﬁed into platinum-resistant (relapse within 6 months) and platinum-sensitive (relapse > 6 months) cohorts following ﬁrst-line therapy, which inﬂuences subsequent treatment strategies. [10] At recurrence, the platinum-sensitive cohort  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/adhm.202404117](https://doi.org/10.1002/adhm.202404117)[ ](https://doi.org/10.1002/adhm.202404117)© 2025 The Author(s). Advanced Healthcare Materials published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are ","cbCain8DawC3bQzu","https://ap.wps.com/l/cbCain8DawC3bQzu","pdf",3022297,15,"English","# Introduction\n## Clinical challenge in ovarian cancer\n## Precision medicine limitations and biomarker gaps\n## Drug repurposing and 3D spheroid modeling\n## High-throughput pipeline and screening outcomes","[{\"question\":\"Why is drug repurposing particularly attractive for ovarian cancer treatment?\",\"answer\":\"Ovarian cancer has limited effective precision medicine options because reliable outcome-predicting biomarkers are scarce. Repurposing leverages existing pharmacological knowledge to rapidly identify new therapies for ovarian cancer.\"},{\"question\":\"What model is used to better reflect ovarian cancer behavior during drug testing?\",\"answer\":\"Patient-derived polyclonal spheroids isolated from ascites fluid are used as a 3D model that closely mimics clinical ovarian cancer behavior, improving relevance compared with traditional 2D systems.\"},{\"question\":\"How did rapamycin perform in combination therapy compared with monotherapy?\",\"answer\":\"Rapamycin showed limited activity as a monotherapy, but it synergized effectively with standard treatments such as cisplatin and paclitaxel in vitro, and in combination with platinum-based therapy it increased cytotoxicity and reduced tumor burden in a syngeneic in vivo model.\"}]","A Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer | PDF",1790170623,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1b8a84621debd0385e0c1f5dcaa1a98.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1976cd4b4dfc8ab21574d5e61af958bb.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/463d265d533d974972393205f8481a14.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0de0e0d7eb3849cc5c1386636073f3cd.webp",980,1287]